Skip to main content
HUAPONT LIFE SCIENCES CO., LTD. logo

HUAPONT LIFE SCIENCES CO., LTD. — Investor Relations & Filings

Ticker · 002004 ISIN · CNE000001JJ6 LEI · 3003009TGXJC0JJVTJ07 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,461 across all filing types
Latest filing 2019-02-01 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002004

About HUAPONT LIFE SCIENCES CO., LTD.

https://www.huapont.com.cn

HUAPONT LIFE SCIENCES CO., LTD. operates as a diversified entity specializing in the research, development, manufacturing, and distribution of pharmaceutical and chemical solutions. The company holds a prominent position in the dermatology sector, providing a comprehensive range of therapeutic products for various skin disorders. Its pharmaceutical operations extend to the production of high-quality active pharmaceutical ingredients (APIs) and finished dosage forms. Beyond human health, the organization maintains a significant footprint in the agrochemical sector, focusing on the development and supply of crop protection products, including herbicides and pesticides. The company also integrates healthcare services into its business model, overseeing the operation of medical facilities and specialized clinics. Its strategic focus centers on technological advancement and the maintenance of a robust supply chain to support its global commercial activities.

Recent filings

Filing Released Lang Actions
独立董事关于第七届董事会第六次会议相关事项的事前认可意见和独立意见
Board/Management Information Classification · 95% confidence The document is a formal statement from independent directors of 华邦生命健康股份有限公司 regarding their pre-approval and independent opinions on two matters: a related-party transaction involving acquisition of equity in another company, and the application for issuance of short-term financing bonds. The document references compliance with corporate governance rules and legal procedures, and provides independent directors' opinions on these corporate actions. It does not contain financial statements or detailed financial data, nor is it a report of financial results or an announcement of voting results. It is a governance-related document focusing on board-level approvals and independent director opinions on corporate matters. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by the board or senior management, including independent director opinions on corporate transactions and financing.
2019-02-01 Chinese
关于全资子公司药品盐酸左西替利嗪片通过仿制药一致性评价的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the approval of a pharmaceutical product by a regulatory authority (国家药品监督管理局 - National Medical Products Administration). It discusses the impact of this approval on the company's business and includes a risk warning to investors. The document is short (720 characters) and does not contain financial statements, detailed financial data, or comprehensive report content. It is an announcement of a regulatory approval event rather than a financial report or detailed management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2019-02-01 Chinese
第七届董事会第六次会议决议公告
Board/Management Information Classification · 95% confidence The document is titled as a resolution announcement from the company's seventh board of directors meeting. It details the meeting's agenda, voting results on various proposals including acquisition of equity, issuance of short-term financing bonds, financial budget report, and convening a shareholders meeting. It references announcements published in newspapers and on a financial information website. The document is a formal announcement of board meeting resolutions and related decisions, not a full report or financial statement. It does not contain detailed financial data or comprehensive report content. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors.
2019-02-01 Chinese
关于收购重庆市卓瑞纵横生物技术有限公司部分股权暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the acquisition of a partial equity stake in a company (Chongqing Zhuorui Zongheng Biotechnology Co., Ltd.) by Huabang Life Health Co., Ltd. It details the transaction terms, related party information, pricing policy, and the impact on the listed company. It includes financial data of the target company and mentions an audit report but does not itself contain a full audit report or financial statements. The document is a formal announcement of a capital transaction and related party transaction, not a full financial report or audit report. It fits best under Capital/Financing Update (CAP) as it concerns a financing/capital structure change through acquisition of equity. The document length (5745 characters) and content confirm it is a detailed announcement rather than a brief notice or a full annual/interim report.
2019-02-01 Chinese
关于回购公司股份的进展公告
Transaction in Own Shares Classification · 95% confidence The document is titled as an announcement regarding the progress of the company's share repurchase (回购公司股份的进展公告). It details the dates and approvals related to the share buyback plan, the quantities and prices of shares repurchased, and compliance with stock exchange rules. The content focuses on reporting the ongoing status of the company's share repurchase program, including specific figures and dates. It is not a full financial report, earnings release, or management discussion, but a progress update on share repurchase activity. According to the filing definitions, this fits the category of 'Transaction in Own Shares' (POS), which covers reports of the company buying back its own shares. The document length is short (1131 characters), but it contains substantive information about the repurchase progress, not just a notice of report publication. Therefore, the correct classification is POS with high confidence.
2019-01-02 Chinese
2018年第四次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a resolution announcement from the 2018 fourth extraordinary general meeting of shareholders of Huabang Life Health Co., Ltd. It details the meeting attendance, voting results on various proposals including issuance of corporate bonds, authorization to the board, credit and guarantee matters, and related legal opinions. The content is focused on the official voting results and resolutions passed at the shareholders meeting. There is no financial data or report analysis, nor is it a presentation or management discussion. The document is an official announcement of voting results from a shareholders meeting, which fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is over 5,000 characters and contains detailed voting results, confirming it is not a brief announcement or a report publication notice.
2018-12-24 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.